High-throughput proteomic profiling to evaluate differentiation syndrome with menin inhibition

Product:

Inflammation Panel 250

Topic:

Oncology

Disease Area:

Differentiation Syndrome associated with AML therapy

Sample Type:

Plasma, Serum

Topic/Product:

Inflammation Panel 250

Disease Area:

Differentiation Syndrome associated with AML therapy

Sample Type:

Plasma, Serum

Abstract

High-throughput proteomic profiling provides a comprehensive analysis of systemic cancer effects and tumor microenvironment interactions. Characterizing soluble proteins driving inflammation in acute myeloid leukemia (AML) offers insight into inflammatory diseases like differentiation syndrome related to AML therapies like menin inhibitors. We present our application of nucleic acid-linked immuno-sandwich assay, a novel technology leveraging next-generation sequencing for high-throughput, ultrasensitive characterization of secreted inflammatory proteins in plasma or serum. Here, we report its use to identify dynamic soluble protein changes during treatment and at the time of suspected differentiation syndrome in pediatric AML patients treated with the menin inhibitor revumenib (NCT04065399 and NCT05360160).

Authors & Affiliations

Miriam B. Garcia¹, Bofei Wang², Irtiza Sheikh¹, Georgina El Hajjar², David McCall¹, Cesar Nunez¹, Amber Gibson¹, Philip L. Lorenzi³, Ghayas C. Issa², Branko Cuglievan¹, and Hussein A. Abbas²⁴

¹ Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
³ Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
⁴ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.